Regeneron Pharmaceuticals, Inc.
Get Full AccessDescription
- Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema myopic choroidal neovascularization and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis in adults, and asthma in adults and adolescents Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults and Kevzara solution for subcutaneous injection for treating rheumatoid arthritis in adults. In addition, the company offers Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer. Further, it offers Inmazeb injection for infection caused by Zaire ebolavirus and develops product candidates for treating patients with eye, allergic and inflammatory, cancer, cardiovascular and metabolic, pain, infectious, and other diseases. The company has collaboration and license agreements with Sanofi Bayer Teva Pharmaceutical Industries Ltd. Mitsubishi Tanabe Pharma Corporation Alnylam Pharmaceuticals, Inc. Roche Pharmaceuticals and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services. It has collaborations with Zai Lab Limited Intellia Therapeutics, Inc. and Biomedical Advanced Research Development Authority. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York.
-
Headquarters:777 Old Saw Mill , Tarrytown, New York, United States
More -
Phone Number: +1 914-847-7000
-
Website: https://www.regeneron.com
-
Employees:9030
-
Revenue:> $1B
-
Legal Name:Regeneron Pharmaceuticals, Inc.
-
Regeneron Pharmaceuticals, Inc.'s Social Media
-
Is this data correct?
-
| NAICS Code: 621111 |
NYSE: REGN
Show More
Sell more in less time!
Buyer intent data, anonymous visitor identification, first party data integration backed by a massive contact database that will supercharge your sales team. Schedule a demo to learn more!
View Employees
Frequently Asked Questions regarding Regeneron Pharmaceuticals, Inc.
-
Where are Regeneron Pharmaceuticals, Inc.'s Headquarters?
Regeneron Pharmaceuticals, Inc.'s Headquarters are in 777 Old Saw Mill ,Tarrytown,New York,United States
-
What is Regeneron Pharmaceuticals, Inc.'s phone number?
Regeneron Pharmaceuticals, Inc.'s phone number is +1 914-847-7000
-
What is Regeneron Pharmaceuticals, Inc.'s stock symbol?
Regeneron Pharmaceuticals, Inc.'s stock symbol is REGN
-
What is Regeneron Pharmaceuticals, Inc.'s official website?
Regeneron Pharmaceuticals, Inc.'s official website is https://www.regeneron.com
-
What is Regeneron Pharmaceuticals, Inc.'s Revenue?
Regeneron Pharmaceuticals, Inc.'s revenue is > $1B
-
What is Regeneron Pharmaceuticals, Inc.'s NAICS code?
Regeneron Pharmaceuticals, Inc.'s NAICS code is 621111
-
How many employees are working in Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. has 9030 employees
-
What is Regeneron Pharmaceuticals, Inc.'s Industry?
Regeneron Pharmaceuticals, Inc. is in the industry of Biotechnology